Rilotumumab 化学特性,用途語,生産方法
説明
Rilotumumab is an anti-HGF antibody that prevents ligand binding to MET and its activation.
臨床応用
A phase I/II trial of rilotumumab in combination with erlotinib was evaluated in previously treated NSCLC patients with metastatic disease. The results indicated a favorable safety profile and success in terms of disease control rate. A phase Ib/II trial of rilotumumab or ganitumab in combination with etoposide and carboplatin or cisplatin was evaluated in extensive-stage SCLC patients.
Rilotumumab 上流と下流の製品情報
原材料
準備製品